The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Open accessAbstract
Introduction: 177Lutetium-[DOTA°,Tyr3]octreotate (177Lu-DOTATATE) is a type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients. The therapy approval was based on findings from the randomized international phase III NETTER-1 trial as well as outcome data from a large European registry. The mechanism of the drug stems directly from its structure: a somatostatin analog (octreotate) selectively binding to somatostatin receptor expressing cells and being internalized, along with a chelated beta-emitting isotope 177Lu.Areas Covered: Herein we describe the pharmacology, clinical efficacy and adverse event data from prospective and retrospective studies with 177Lu-DOTATATE. We discuss the role of 177Lu-DOTATATE within the current treatment landscape for GEP NET patients.Expert Opinion: 177Lu-DOTATATE represents a unique addition to the treatment armamentarium for GEP NETs because of its potential to elicit tumor cytoreduction, which is rare among other existing treatment options, and prolonged disease control. Where 177Lu-DOTATATE fits into the treatment sequence for GEP NET patients remains an area of active investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“An excellent example is 177Lu-DOTATATE, a radiolabelled somatostatin analogue, used to treat neuroendocrine tumors (NETs) [91].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasari, A. N., Shen, C., Halperin, D. M., Zhao, B., Zhou, S., Xu, Y., Shih, Y. T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,457 · cited 2×
“Article highlights ● 177Lu-DOTATATE is a radiolabeled somatostatin agonist (SSA), which is approved for the treatment of somatostatin receptor positive welldifferentiated gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients in Europe, the United States, and Canada.”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · cited 1×
“The NETTER-1 study was a randomized phase III trial in patients with progressive metastatic or unresectable well-differentiated midgut neuroendocrine tumors [34].”
BackgroundSelf-citationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · cited 1×
“proven cytostatic activity for pancreatic NETs only [8].”
BackgroundRinke, A., Müller, H., Schade‐Brittinger, C., Klose, K., Barth, P. J., Wied, M., Mayer, C., Aminossadati, B., Pape, U., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,507 · cited 1×
“or those with hormonal over-production leading to syndromes, long-acting somatostatin agonists (SSAs) have been the cornerstone of first-line therapy [4,5].”
BackgroundLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,937 · cited 1×
“or those with hormonal over-production leading to syndromes, long-acting somatostatin agonists (SSAs) have been the cornerstone of first-line therapy [4,5].”
Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E. M., Tomášek, J., Raderer, M., Lahner, H., Voi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,290
Self-citationNothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B. T., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 766 · cited 1×
“Gastroenteropancreatic (GEP) NETs represent the most common subtype of well-differentiated NETs, comprising more than 70% of these neoplasms [2].”
BackgroundStrosberg, J., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J. F., & Kvols, L. K. (2010) · Cancer · doi:10.1002/cncr.25425 · Cited by 763
Self-citationImhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H. F., Mäcke, H. R., Rochlitz, C. F., Müller‐Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641 · cited 1×
“2% experienced permanent nephrotoxicity (grade ≥ 4) [29].”
Research works printed but not linked: 4
- Barone R, 2005, J Nucl Med, 46, 99S
- Strosberg J, 2018, J Clin Oncol, 36(25):2578–258
- Zhang J, 2019, J Nucl Med, 60, 560
- Forrer F, 2005, J Nucl Med, 46, 1310
Cited by
Sorted by citations
Items 101–135 of 135
Kumar, S. A., Selvaraj, V. K., & Srivastava, M. K. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005990 · Cited by 1
Graves, S. A., Bushnell, D. L., Schultz, M. K., Jain, S., Bodeker, K. L., & Menda, Y. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270083 · Cited by 1
Spetz, J. K. E., Montelius, M., Berger, E., Johansson, J. A. M., Rassol, N., Ljungberg, M., & Forssell-Aronsson, E. B. (2026) · BMC Cancer · doi:10.1186/s12885-026-16975-3 · Cited by 1
Shen, Z., Zhang, X., Li, Q., & Wang, R. (2024) · Radiology Case Reports · doi:10.1016/j.radcr.2024.03.051 · Cited by 1
“However, in cases of advanced-stage NENs or neuroendocrine carcinoma (NEC), where SSTR expression may be reduced, the sensitivity of 177 Lu-DOTATATE decreases, highlighting the complexity of imaging and treating these tumors [21] .”
BackgroundRepurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma
Elajami, M. K., Burton, L. P., Bahmad, H. F., Chaaya, G., & Schwartz, M. (2022) · Current Oncology · doi:10.3390/curroncol29100594 · Cited by 1
Işıkçı, N. İ., Abuqbeitah, M., & Demır, M. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.08.003
Konuparamban, A., Nautiyal, A., Jha, A. K., Mithun, S., Srichandan, T., Puranik, A. D., & Rangarajan, V. (2024) · Health and Technology · doi:10.1007/s12553-024-00867-2
Radiopharmaceuticals and Systemic Therapies for Neuroendocrine Tumors
Wolin, E. M., Ghesani, M. V., Corbett, V., Gavane, S. C., & Kulkarni, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51192-0_90-1
Identifying New Molecular Modalities for Radionuclide Therapy Using Macrocyclic Peptide Mimetics
Charych, D. H., & Harding, T. A. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00217
Glypican-3 (GPC3) Targeted Radiopharmaceuticals for Treatment of Liver Cancer
He, R., Mezo, A. R., & Chen, G. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00202
Targeted Radiopharmaceuticals: Clinical Development and Commercial Landscape
Agarwal, E., & Srivastava, V. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00001
Pellè, E., Al‐Toubah, T., El-Haddad, G. E., Morse, B. G., Konda, B., Sukrithan, V., & Strosberg, J. (2025) · Endocrine Oncology · doi:10.1530/eo-25-0033
Self-citationRadiopharmaceuticals: from discovery to theranostics
Chen, J., Tang, S., & Lü, P. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10237-5
Direct Conversion for SPECT Imaging
Iniewski, K. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-94005-7_5
Anticancer Therapy Against Glioma by Peptide-Based Therapeutics
Mitra, S., Das, S., Mukherjee, S., Karati, D., & Meur, S. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10755-6
“The homing peptide, commonly referred to as the carrier, is the initial part of PDCs and is in the role of tumor targeting (Das et al. 2019).”
Self-citationTheranostics in pancreatic cancer
Singh, R. K., Yadav, A. K., Dada, R., Tiwari, P., Kumar, A., Yadav, A., Gowerdhan, S. A., Paul, G., Pandey, S. K., Singh, S., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34199-1.00005-3
Sánchez-Arreguín, R., Ahumada-Ayala, M., Santibañez-Silva, V., Bautista-Martínez, B., & Gallegos-Garza, C. (2025) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2025.02.004
Sánchez-Arreguín, R., Ahumada-Ayala, M., Santibañez-Silva, V., Bautista-Martínez, B., & Gallegos-Garza, C. (2025) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2025.10.014
Should We Continue Liver Transplantation in Spain for Hepatic Metastases from Neuroendocrine Tumors?
Robledo, A. B., Montalvá, E. M., Vila, M., Lladó, L., López, V., Gastaca, M., Tomé, S., Ramia, J. M., Nuño, J., Rotellar, F., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030938
Desarrollo de radiofármacos para la teragnosis de tumores neuroendocrinos
Torres, F. D., Iruela, J. A. P., & Bautista‐Aguilera, Ó. M. (2026) · FarmaCiencia Revista de Divulgación Científica · doi:10.37536/fc.3341
Preparation and preliminary biological evaluation of [131I]I-yg-15 peptide
Wang, Y., Wang, Y., Cao, X., Kuang, Z., Ma, L., Zhang, L., Liu, Y., Li, Z., & Li, Q. (2026) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-026-10824-0
Kristiansen, S. K., Dernjani, N., Bruland, Ø. S., Edin, N. F. J., & Juzeniene, A. (2026) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-026-00444-0
“…in oncology, as demonstrated by the clinical implementation of [ 177 Lu]Lu-DOTATATE for somatostatin receptor-positive neuroendocrine tumors (Das et al. 2019), and [ 177 Lu] Lu-PSMA-617 for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer…”
Radiofarmaceutyki stosowane w badaniach onkologicznych: przegląd.
Pławska, M., & Cholewiński, W. (2026) · Letters in Oncology Science · doi:10.21641/los.2026.1.1.273
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates
Walsh, S. J., Wood, F., DeMars, L. R., & Bennett, G. S. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2683842
Shi, J. J., Yao, M., Yin, P., Lu, J., Yang, J., Zhao, J., Qiao, Z., & Lu, C. (2026) · Cancer Control · doi:10.1177/10732748261459153
“17,30,31 Our study also demonstrates that the 5-year OS and CSS rates for advanced GEP-NENs patients who received internal radiation therapy can exceed 50%.”
Clinical and translational landscape of rare-earth-based imaging and therapeutic agents
Yu, Z., Ming, J., & Zhang, F. (2026) · Journal of Rare Earths · doi:10.1016/j.jre.2026.06.017
Radiolabeling and physicochemical characterization of terbium-161 DOTATATE
Tanwar, K. S., Sawant, V., Rawat, D., Dubey, V., Shaikh, A. W., Dwivedi, P., Dev, I. D., Choudhury, S., & Agrawal, A. (2026) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002201
Heavy Metal Chelation and Bioprotective Activity of Dextran-DOTA Macromolecular Conjugate
Guajardo, S., Wood, H. B., Deng, C., Alpha, N., & Sydlik, S. A. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c00847
Translational bioengineering perspectives on biosensors and nanorobotics for cancer theranostics
Rawat, M., Jha, M. K., Agrawal, P. K., Bhatt, A., & Rai, S. K. (2026) · Discover Sensors · doi:10.1007/s44397-026-00087-5
Li, Y., Pu, K., Li, D.-Q., Zhao, Y.-J., Cai, Q.-X., Zhou, X., Li, S.-Q., Chen, Y., Zhou, Z.-J., & Liu, Y. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103376
Fan, X., Logan, K., Li, H., Chen, W., Huang, J., Morse, M. A., & Shi, C. (2026) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2026.00013
Radiopharmaceuticals and Systemic Therapies for Neuroendocrine Tumors
Wolin, E. M., Ghesani, M. V., Corbett, V., Gavane, S. C., & Kulkarni, R. (2026) · Springer eBooks · doi:10.1007/978-3-031-49762-9_90
Hybrid Imaging in the Head and Neck
Kirsch, C. F. (2026) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2026.07.012
Mitra, P., Panja, A., Pirthwar, R., Lubin, B. C. R., Tobi, D., & Gellerman, G. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110607
Radioimmunotherapy: Mechanisms, Strategies, and Advances in Therapeutic Enhancement
Naqvi, D. S. A. R., Fatima, S. M., Waji-Ul-Hassan, S. M., Gursal, S. A., Fatima, S., Imran, M. B., Wasim, M., Ramadan, M. F., & Lodhi, N. A. (2026) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1177/10849785261486288
Metadata
- Authors
- Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J.
- Affiliations
- Vanderbilt University Medical Center (US)
- Department of GI Oncology, Moffitt Cancer Center, Tampa, FL, USA
- Moffitt Cancer Center (US)
- Corresponding author
- Das, Satya
- Venue
- Expert Review of Gastroenterology & Hepatology
- Publisher
- Informa UK Limited
- Published
- 2019-10-30
- Volume
- 13
- Issue
- 11
- Pages
- 1023-1031
- ISSN
- 1747-4124 (ISSN-L)
- 1747-4132
- PMC
- PMC7227421
- OpenAlex
- W2981499856
- Cited by
- 135
- References
- 53
- Citations by year
- 2026: 23 · 2025: 32 · 2024: 32 · 2023: 15 · 2022: 20 · 2021: 9 · 2020: 4
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Review of Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- 177Lu-DOTATATE, peptide receptor radionuclide therapy, gastroenteropancreatic neuroendocrine tumors, somatostatin receptors, octreotate, NETTER-1 trial, treatment efficacy, adverse events, treatment sequencing
- MeSH terms
- Animals, Gastrointestinal Neoplasms, Humans, Organometallic Compounds, Pancreatic Neoplasms, Octreotide, Treatment Outcome, Neuroendocrine Tumors, Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
